Ashley A. Wilkins

Ms. Ashley A. Wilkins

Louisiana State University Health Sciences Center Shreveport
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
PGPatrick Gellings
Patrick Gellings
Ashley A. WilkinsAshley A. Wilkins
Ashley A. Wilkins
Lisa MoriciLisa Morici
Lisa Morici
Acinetobacter baumannii has been a major cause of nosocomial infections for decades. The absence of an available vaccine coupled with emerging multidrug resistance has prevented the medical community from effectively controlling this human pathogen. Furthermore, the ongoing pandemic caused by SARS-CoV-2 has increased the risk of hospitalized patients developing ventilator-associated pneumonia caused by bacterial opportunists including A. baumannii. The shortage of antibiotics in the development pipeline prompted the World Health Organization to designate A. baumannii a top priority for the development of new medical countermeasures, such as a vaccine. There are a number of important considerations associated with the development of an A. baumannii vaccine, including strain characteristics, diverse disease manifestations, and target population. In the past decade, research efforts have revealed a number of promising new immunization strategies that could culminate in a safe and protective vaccine against A. baumannii. In this review, we highlight the recent progress in the development of A. baumannii vaccines, discuss potential challenges, and propose future directions to achieve an effective intervention against this human pathogen.

1 May 2017
Verified
Conference Paper
Closed access
MRMagesh T Rajan
Magesh T Rajan
Ashley A. WilkinsAshley A. Wilkins
Ashley A. Wilkins
BPBrandon Phung
Brandon Phung
Summary form only given. Our Plasma Engineering Research Lab (PERL) has been developing a variety of non-thermal plasma discharges for a range of applications. One of our recent development is a portable table-top atmospheric pressure non-thermal air plasma system using a resistive barrier discharge configuration that has been designed and developed for bacterial decontamination and sterilization of a range of items in a very simple one-touch operation. In this work, we will present the results of inactivation efficacies of bacteria that causes hospital acquired infections (HAI). The portable table-top atmospheric pressure non-thermal air plasma system is designed to inactivate bacteria in medical instruments of varied surface texture such as metals, polymers and glasses. The portable table-top atmospheric pressure non-thermal air plasma system is designed to function at standard 50-60 Hz low frequency AC power input and in the ambient air. The core resistive barrier plasma setup used in this system is well characterized by our group. Ozone, and nitric oxides (NO) were observed to be the predominant long lived reactive species produced by the portable table-top atmospheric pressure non-thermal air plasma system. The results of the bacterial inactivation on variety of medical surfaces will be presented in detail.